(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 July 2021 (22.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/144476 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 47/18* (2017.01)
A61K 9/00 (2006.01) *A61K 47/02* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/EP2021/053805

(22) International Filing Date:
17 February 2021 (17.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20157963.8	18 February 2020 (18.02.2020)	EP
20171240.3	24 April 2020 (24.04.2020)	EP
20180645.2	17 June 2020 (17.06.2020)	EP
20180832.6	18 June 2020 (18.06.2020)	EP
21150056.6	04 January 2021 (04.01.2021)	EP
21151004.5	11 January 2021 (11.01.2021)	EP
21154657.7	02 February 2021 (02.02.2021)	EP

(71) Applicant: **NOVO NORDISK A/S** [DK/DK]; Novo Allé, 2880 Bagsværd (DK).

(72) Inventors: **SANDER, Tommy**; Novo Allé, 2880 Bagsværd (DK). **POULSEN, Christian**; Novo Allé, 2880 Bagsværd (DK). **HANSEN, Rosa, Rebecca, Erritzøe**; Novo Allé, 2880 Bagsværd (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)*

(54) Title: PHARMACEUTICAL FORMULATIONS

(57) Abstract: Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

WO 2021/144476 A1